{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:21:05Z","timestamp":1793524865325,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"publisher","award":["14-IRB154"],"award-info":[{"award-number":["14-IRB154"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2025-C-012"],"award-info":[{"award-number":["CSH-2025-C-012"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2025-C-023"],"award-info":[{"award-number":["CSH-2025-C-023"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diabres.2025.113073","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:05:50Z","timestamp":1766621150000},"page":"113073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation"],"prefix":"10.1016","volume":"231","author":[{"given":"Shan-Ho","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Hung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-1685","authenticated-orcid":false,"given":"Yu-Nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yuh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.113073_b0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.diabres.2025.113073_b0010","article-title":"Effectiveness of Immune Checkpoint Inhibitors in Various Tumor Types Treated by Low, Per-Weight, and conventional Doses at a Tertiary Care Center in Mumbai","volume":"10","author":"Patel","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.diabres.2025.113073_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011271","article-title":"Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations","volume":"13","author":"Wu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.diabres.2025.113073_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e21104","article-title":"Obesity diabetes and dyslipidemia as determinants of immune checkpoint inhibitors response in non-small cell lung cancer","volume":"40","author":"Awidi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diabres.2025.113073_b0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.trecan.2025.04.010","article-title":"Repurposing glucose-lowering drugs for cancer therapy","volume":"11","author":"Luconi","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.diabres.2025.113073_b0030","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acs.chemrestox.4c00067","article-title":"Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies","volume":"37","author":"Grice","year":"2024","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.diabres.2025.113073_b0035","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-22-3116","article-title":"Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in patients with Cancer","volume":"29","author":"Cortellini","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2025.113073_b0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.113073_b0045","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1111\/dom.15869","article-title":"Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: a global retrospective cohort study","volume":"26","author":"Huang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.113073_b0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.113073_b0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.diabres.2025.113073_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103213","article-title":"Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study","volume":"83","author":"Wolff Sagy","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2025.113073_b0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaoncol.2022.5409","article-title":"Association of Body Mass Index with the Safety Profile of Nivolumab with or without Ipilimumab","volume":"9","author":"McQuade","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.diabres.2025.113073_b0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in patients with Type 2 Diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.113073_b0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s43856-025-01066-4","article-title":"Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity","volume":"5","author":"Huang","year":"2025","journal-title":"Communications Medicine"},{"key":"10.1016\/j.diabres.2025.113073_b0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2964","article-title":"Spending on Glucagon-like Peptide-1 Receptor Agonists among US adults","volume":"8","author":"Tsipas","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.113073_b0085","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-20-3855","article-title":"Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group","volume":"27","author":"Harvey","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diabres.2025.113073_b0090","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.113073_b0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2025.113073_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115170","article-title":"Glucagon-like Peptide-1 Agonists Reduce Cardiovascular events in Cancer patients on Immune Checkpoint Inhibitors","volume":"216","author":"Chiang","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.diabres.2025.113073_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4559","article-title":"The effect of GLP-1 receptor agonists on outcomes in metastatic renal cell carcinoma patients undergoing immune checkpoint inhibitor therapy: a retrospective multi-institutional US cohort study","volume":"43","author":"Elchouemi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diabres.2025.113073_b0110","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s11096-018-0706-9","article-title":"Pharmacovigilance in oncology","volume":"40","author":"Baldo","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.diabres.2025.113073_b0115","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of Gastrointestinal adverse events Associated with Glucagon-like Peptide-1 Receptor Agonists for Weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2025.113073_b0120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of Glucagon-like Peptide-1 Receptor Agonist Use with risk of Gallbladder and Biliary Diseases a Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabres.2025.113073_b0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2025.113073_b0130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The Target Trial Framework for Causal Inference from Observational Data: why and when is it Helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2025.113073_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836934","article-title":"Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity","volume":"12","author":"Sieber","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.diabres.2025.113073_b0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.21887","article-title":"GLP-1 RA Use and Survival among older adults with Cancer and Type 2 Diabetes","volume":"8","author":"Radwan","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.113073_b0145","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2337\/dc22-2521","article-title":"Rapid Reduction of HbA1c and Early Worsening of Diabetic Retinopathy: a Real-world Population-based Study in Subjects with Type 2 Diabetes","volume":"46","author":"Sim\u00f3","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.113073_b0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2025.113073_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2025.113073_b0160","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis","volume":"27","author":"Ren","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.113073_b0165","article-title":"The Predictive potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer patients: a Systematic Review and Meta-Analysis","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.diabres.2025.113073_b0170","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2025.113073_b0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1210\/jc.2009-1503","article-title":"Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia","volume":"95","author":"Deane","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.113073_b0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-014-9290-z","article-title":"Cardiovascular and hemodynamic effects of glucagon-like peptide-1","volume":"15","author":"Goodwill","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.diabres.2025.113073_b0185","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.113073_b0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.diabres.2025.113073_b0195","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:10:08Z","timestamp":1778674208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725010885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S0168822725010885"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113073","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113073"}}